Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
| Condition | Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma |
|---|---|
| Phase | Phase 2 |
| Sponsor | University of Alabama at Birmingham |
| Status | Completed |
| Enrollment | 20 participants |
| Interventions | Siltuximab |
| Start date | Nov 15, 2021 |
| Completion date | Jan 20, 2026 |
| Results posted | Jun 3, 2026 |
Summary
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.
Participants With a Complete Response for Cytokine Release Syndrome (CRS)
| Siltuximab | 15 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myel — M.D. Anderson Cancer Center
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (M — National Cancer Institute (NCI)